Literature DB >> 3565942

Natural killer cell function in human lung is compartmentalized.

J C Weissler, L P Nicod, M F Lipscomb, G B Toews.   

Abstract

Natural killer (NK) cells are a subpopulation of lymphocytes capable of killing a variety of neoplastic targets. NK can limit pulmonary metastases in animal models and could be important mediators of tumor defense in human lung. Previous studies in humans have suggested, however, that pulmonary NK cells obtained by bronchoalveolar lavage (BAL) are functionally inert. We purified lymphocytes from human lung tissue and compared the NK activity of these cells with lymphocytes purified from peripheral blood. The activity of NK cells obtained from minced whole lung specimens was comparable to that found in peripheral blood. Monoclonal antibodies to 2 markers found on peripheral blood large granular lymphocytes (LGL) were utilized to determine the phenotype of pulmonary NK cells. Lymphocytes expressing Leu 11b were responsible for pulmonary NK activity as all NK function was abrogated by pretreatment with anti-Leu 11b and complement. In contrast, lymphocytes expressing Leu 7 had little NK activity. Although the frequency of lymphocytes expressing Leu 7 or Leu 11 in blood was comparable, there were significantly more (p less than 0.001) Leu 7+ lymphocytes in the lung than Leu 11+ cells. Immunofluorescent staining of lung tissue demonstrated that LGL expressing Leu 11 were confined largely to the lung interstitium, whereas LGL expressing Leu 7 were frequently located in alveoli and larger airways. These findings suggest that NK function is present in the human lung and that it is compartmentalized with the NK-active Leu 11+ lymphocytes located primarily in the lung interstitium.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3565942     DOI: 10.1164/arrd.1987.135.4.941

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  20 in total

1.  Lymphocyte subsets in subjects exposed to asbestos: changes in circulating natural killer cells.

Authors:  N al Jarad; M Macey; S Uthayakumar; A C Newland; R M Rudd
Journal:  Br J Ind Med       Date:  1992-11

Review 2.  Bronchoalveolar lavage and the immunology of lung cancer.

Authors:  G Semenzato; M Spatafora; C Feruglio; E Pace; V Dipietro
Journal:  Lung       Date:  1990       Impact factor: 2.584

3.  Increased numbers of T lymphocytes with gamma delta-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis.

Authors:  B Balbi; D R Moller; M Kirby; K J Holroyd; R G Crystal
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

4.  Acute stress reduces intraparenchymal lung natural killer cells via beta-adrenergic stimulation.

Authors:  O Kanemi; X Zhang; Y Sakamoto; M Ebina; R Nagatomi
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

Review 5.  Innate immunity to Aspergillus species.

Authors:  Stacy J Park; Borna Mehrad
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 6.  Cytotoxic effector cells of the immune system.

Authors:  P Groscurth
Journal:  Anat Embryol (Berl)       Date:  1989

7.  Innate immune processes are sufficient for driving silicosis in mice.

Authors:  Celine A Beamer; Christopher T Migliaccio; Forrest Jessop; Melanie Trapkus; Dorothy Yuan; Andrij Holian
Journal:  J Leukoc Biol       Date:  2010-06-24       Impact factor: 4.962

8.  Immunomodulatory effects of pulmonary surfactant on natural killer cell and antibody-dependent cytotoxicity.

Authors:  M L Wilsher; D A Hughes; P L Haslam
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

9.  Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis.

Authors:  Stacy J Park; Molly A Hughes; Marie Burdick; Robert M Strieter; Borna Mehrad
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 10.  Chronic inflammation and asthma.

Authors:  Jenna R Murdoch; Clare M Lloyd
Journal:  Mutat Res       Date:  2009-09-19       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.